Navigation Links
Optimer Pharmaceuticals, Inc. Announces Presentation at ECCMID of Post-Hoc Subgroup Analysis of DIFICID in Adult Cancer Patients Being Treated for Clostridium difficile-Associated Diarrhea (CDAD)
Date:3/30/2012

ment of CDAD in adults.  These studies served as the basis of approval for DIFICID by the U.S. Food and Drug Administration (FDA) in May 2011.

The subgroup analysis evaluated the treatment of 183 CDAD patients with active cancer – 153 of whom received 8 days or more of treatment – compared to 922 CDAD patients without cancer who were among the modified intent to treat population of the Phase 3 studies (N=1105).  To be included in the analysis, patients must have had a current diagnosis of cancer at the time of CDAD diagnosis and were receiving various forms of treatment. Patients with active cancer (solid tumor or hematologic malignancy) were identified from medical history, concomitant medication indications, and adverse event entries in the case report forms. Clinical endpoints assessed in the 153 patients, included clinical cure at the end of treatment, recurrence of CDAD after clinical cure during the four week follow-up, and sustained clinical response (clinical cure with no recurrence in the four-week follow-up period).

About DIFICID® (fidaxomicin) Tablets
DIFICID is the first antibacterial drug indicated for Clostridium difficile-associated diarrhea (CDAD) to be approved in more than 25 years. It is indicated for the treatment of CDAD in adults 18 years of age or older. DIFICID is administered in 200 mg tablets given orally twice daily.

Important Safety Information for DIFICID
DIFICID should not be used for systemic infections. Only use DIFICID for infection proven or strongly suspected to be caused by C. difficile. Prescribing DIFICID in the absence of a proven or strongly suspected C. difficile infection is unlikely to provide benefit to the patient and increases the risk of the development of drug resistant bacteria. The most common adverse reactions are nausea (11%), vomiting (7%), abdominal pain (6%), gastrointestinal hemorrhage (4%), anemia (2%), and neutropenia
'/>"/>

SOURCE Optimer Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Optimer Reports Fourth Quarter and Fiscal Year 2011 Financial Results
2. Optimer Pharmaceuticals to Host Conference Call and Webcast to Discuss Fourth Quarter and FY 2011 Financial Results
3. Optimer Pharmaceuticals to Present at the 32nd Annual Cowen Health Care Conference
4. Optimer Pharmaceuticals Provides Update on DIFICID® (fidaxomicin) Tablets Launch
5. Optimer Pharmaceuticals to Present at the 30th Annual J.P. Morgan Healthcare Conference
6. Optimer Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
7. Optimer Pharmaceuticals to Present at BioCentury Newsmakers Conference
8. Optimer Pharmaceuticals and Astellas Receive Positive Opinion from CHMP for European Approval of DIFICID™
9. Optimer to Provide DIFICID™ Launch Update at Morgan Stanley Global Healthcare Conference
10. Optimer Pharmaceuticals DIFICID Featured in 11 Presentations at 51st ICAAC
11. Optimer Pharmaceuticals to Present at September 2011 Investor Conferences
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... NEW YORK , January 15, 2014 ... BreedIT Ltd., the exclusive worldwide distributor of highly sophisticated ... that on January 7, 2014, the Company,s board of ... Ben-Zion Weiner as its new member of the ...
(Date:1/15/2014)... PALM BEACH GARDENS, Fla. , Jan. 15, 2014  In an ... C. difficile and TB in ambulances and other transport vehicles, an ... being used by rescue personnel for the first time. ... coming in contact with these deadly pathogens, West Palm ...
(Date:1/15/2014)... 2014 MultiCell Technologies, Inc. (OTC Bulletin Board: ... application concerning composition of matter, biological targets, mechanism of ... death.  This patent application describes a ... molecules (VSRNAs) which interfere with the basic homeostatic cellular ...
Breaking Medicine Technology:BreedIT (OTC: BRDT) Appoints Chemistry and Pharmaceutical Industry Expert Dr. Ben-Zion Weiner to Its Board of Directors 2BreedIT (OTC: BRDT) Appoints Chemistry and Pharmaceutical Industry Expert Dr. Ben-Zion Weiner to Its Board of Directors 3Superbugs No Longer Ride In Rescue Vehicles 2MultiCell Technologies Files Patent Application Covering New Class of RNA Therapeutics 2MultiCell Technologies Files Patent Application Covering New Class of RNA Therapeutics 3
... industry is expecting a busy summer this year, and ... Day weekend, more hotels and resorts are raising their ... according George Clarke, CEO of UMF Corporation, a developer ... hotels and resorts adopting environmental hygiene practices developed for ...
... SAN FRANCISCO, May 22, 2012  Boehringer Ingelheim announced ... the investigational compound tiotropium delivered once-daily via the ... moderate persistent asthma. The data were presented at ... Society (ATS 2012). Boehringer Ingelheim announced that a ...
Cached Medicine Technology:With Busy Summer Forecast Ahead, More Hotels Are Raising Hygiene Standards, Says UMF Corporation 2Boehringer Ingelheim Presents First Data for Tiotropium in Adolescents with Moderate Persistent Asthma 2Boehringer Ingelheim Presents First Data for Tiotropium in Adolescents with Moderate Persistent Asthma 3Boehringer Ingelheim Presents First Data for Tiotropium in Adolescents with Moderate Persistent Asthma 4
(Date:4/24/2014)... the corresponding terminology, and the relevance of palliation ... publications on randomized controlled trials (RCTs). This is ... Institute for Quality and Efficiency in Health Care ... report. , Together with external experts, IQWiG analysed ... lung cancer, malignant melanoma, and pancreatic cancer. For ...
(Date:4/24/2014)... 4/24/14) Dartmouth has been awarded one of 30 ... as a Lead Academic Participating Site in its new ... recipients are a select groups of investigators charged with ... cooperative groups., The NCTN grant system reflects recommendations from ... streamlines operations to achieve four goals:, Faster ...
(Date:4/23/2014)... A pilot study by Massachusetts General Hospital (MGH) investigators ... unusual treatment for a serious medical problem use ... diarrhea caused by the Clostridium difficile ( ... published online in the journal Clinical Infectious Diseases ... fecal material from donors unrelated to patients was as ...
(Date:4/23/2014)... O,Shea, M.D., scientific director at the National Institute of ... named the 2014 recipient of the Ross Prize in ... journal Molecular Medicine . The award will be ... of Sciences in Manhattan, followed by scientific presentations by ... of the National Institutes of Health. , The award, ...
(Date:4/23/2014)... an important enzyme pathway that helps prevent new cells ... condition that has been directly linked to cancer and ... found that near the end of cell division, the ... breaks in DNA are fully repaired before the parent ... This process helps safeguard against some of the most ...
Breaking Medicine News(10 mins):Health News:Palliation is rarely a topic in studies on advanced cancer 2Health News:Palliation is rarely a topic in studies on advanced cancer 3Health News:Dartmouth awarded lead role in NCI clinical trials network 2Health News:Dartmouth awarded lead role in NCI clinical trials network 3Health News:Use of frozen material for fecal transplant successfully treats C. difficile infection 2Health News:Use of frozen material for fecal transplant successfully treats C. difficile infection 3Health News:NIH scientist to receive Ross Prize in Molecular Medicine 2Health News:Study identifies enzymes that help fix cancer-causing DNA defects 2
... of terminally ill cancer patients, researchers at Dana-Farber Cancer ... cope with their illness are more likely to receive ... that often entails a lower quality of life in ... more religious patients often prefer aggressive end-of-life (EOL) treatment. ...
... economic crisis contributing to greater workplace stress, providing effective ... than ever. , Unfortunately, the approach most companies take ... unlikely to produce the best outcomes for either their ... Florida State University College of Medicine researcher. , Kathryn ...
... March 17 A federal jury in Miami today ... with a $5.3 million Medicare fraud scheme, Acting Assistant ... and U.S. Attorney R. Alexander Acosta of the Southern ... court in Miami, a jury found David Rothman, M.D., ...
... following event was announced today by the American Red ... Los Angeles Red Cross is hosting a lunch reception ... (EOC), which is ready to be activated during major ... the size of Hurricane Katrina. A video with earthquake ...
... , ... Denver -- As part of its ongoing commitment to encourage ... (AWWA), the authoritative resource on safe water, today announced it will partner ... in Las Vegas., , , , ,Debuted last year by the Southern ...
... but figures decline, report finds , , TUESDAY, March 17 ... abuse in the United States have risen dramatically over ... abuse admissions in 1997 to 5 percent in 2007, ... Alcohol was still the leading cause (40 percent) of ...
Cached Medicine News:Health News:Link between religious coping and aggressive treatment in terminally ill cancer patients 2Health News:Link between religious coping and aggressive treatment in terminally ill cancer patients 3Health News:Researcher wins $2.6 million grant for depression care study 2Health News:Researcher wins $2.6 million grant for depression care study 3Health News:Jury Convicts Two Doctors and Two Medical Assistants in $5.3 Million Medicare Fraud Scam 2Health News:Jury Convicts Two Doctors and Two Medical Assistants in $5.3 Million Medicare Fraud Scam 3Health News:Jury Convicts Two Doctors and Two Medical Assistants in $5.3 Million Medicare Fraud Scam 4Health News:State-of-the-Art Preparedness: L.A. Red Cross Opens Advanced Emergency Operations Center 2Health News:AWWA partners with WaterSmart Innovations conference 2Health News:Admissions for Prescription Painkiller Abuse on Rise 2
Plastic Block Filing Cabinet is a durable, six-drawer unit that holds up to 1500 slides....
Shandon Carousel Cassette MicroWriter™ is a carousel-type cassette marking system....
Micro-slide cabinet space saving design, stores as many as 54,000 slides in only two square feet of floor space. Cabinets and base come in 3 colors....
Fisherbrand* Micro Slide Cabinet is made of heavy gauge, reinforced steel....
Medicine Products: